Surgical Robotics Technology
- Presented successful cases of choledochal cyst excision and extended cholecystectomy using Revo-i
- Entire procedures of complex biliary surgeries in the hepatobiliary-pancreatic field performed with Revo-i
meerecompany announced on May 6 that a paper presenting clinical outcomes of complex biliary surgeries performed using its surgical robot, Revo-i, received the JMIS Best Paper Award at the 58th Congress of the Korean Society of Endoscopic and Robotic Surgery and the 16th International Symposium, also known as KSERS 2026. The event was held from April 23 to 25 at Lotte Hotel Seoul.
The JMIS Best Paper Award is presented to researchers whose papers, published in the Journal of Minimally Invasive Surgery, the official journal of the Korean Society of Endo-Laparoscopic & Robotic Surgery, are recognized for outstanding academic value.
The award-winning paper, titled “Pioneering complex biliary surgeries with the Revo-i robotic surgical system: initial cases of choledochal cyst and gallbladder tumor with video,” was authored by Dr. Jae Seung Kang of the Department of Surgery at Hongik Hospital and published in JMIS in 2025.
The paper presents successful cases of highly precise procedures performed using Revo-i, a Korean-made surgical robot. These include choledochal cyst excision with Roux-en-Y hepaticojejunostomy and extended cholecystectomy for a patient with gallbladder cancer.
According to the study, both patients who underwent surgery using Revo-i were discharged in good condition seven days after surgery without complications. Favorable progress was also observed during follow-up. These results demonstrate the technical feasibility and safety of Revo-i in complex hepatobiliary-pancreatic procedures.
In the paper, Dr. Kang stated, “The entire process of complex biliary surgery, which requires both lesion resection and reconstruction, was successfully performed using Revo-i, a Korean-made surgical robot.” He added, “This study confirmed the potential to expand the application of Revo-i beyond simple cholecystectomy to complex hepatobiliary-pancreatic surgeries.”
“We are pleased that the clinical value of Revo-i has been recognized at a prestigious academic society,” said Ho Kun Lee, Executive Vice President and Head of the Surgical Robot Division at meerecompany. “We will continue to accelerate the collection of clinical data to further strengthen the clinical reliability of Revo-i.”
Source: meerecompany
